Terms: = Kidney tumors AND BTG1, P62324, 694, ENSG00000133639 AND Treatment
14 results:
1. Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma.
Dizman N; Govindarajan A; Zengin ZB; Meza L; Tripathi N; Sayegh N; Castro DV; Chan EH; Lee KO; Prajapati S; Feng M; Loo V; Pace M; O'Brien S; Bailey E; Barragan-Carrillo R; Chehrazi-Raffle A; Hsu J; Li X; Agarwal N; Pal SK
Clin Genitourin Cancer; 2023 Oct; 21(5):530-536. PubMed ID: 37495481
[TBL] [Abstract] [Full Text] [Related]
2. Immunotherapy with Autoimmune Complication in Renal Cancer.
Sunil SP; Kumar S; Hussaini S; Kandula S
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116021
[TBL] [Abstract] [Full Text] [Related]
3. [Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].
Qin CP; Song YX; Ding MT; Wang F; Lin JX; Yang WB; DU YQ; Li Q; Liu SJ; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):663-668. PubMed ID: 35950389
[TBL] [Abstract] [Full Text] [Related]
4. Liver Transplant Recipients Who Survive for More Than 10 Years: A Long-Term Survey.
Ayvazoğlu Soy EH; Akdur A; Karakaya E; Moray G; Haberal M
Exp Clin Transplant; 2022 Mar; 20(Suppl 1):20-23. PubMed ID: 35384803
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic nomogram for patients with lung metastatic renal cell carcinoma: a SEER-based study.
Mao W; Fu Z; Wang K; Wu J; Xu B; Chen M
Ann Palliat Med; 2021 Mar; 10(3):2791-2804. PubMed ID: 33549017
[TBL] [Abstract] [Full Text] [Related]
6. Risk of Rare Cancers Among Solid Organ Transplant Recipients.
D'Arcy ME; Castenson D; Lynch CF; Kahn AR; Morton LM; Shiels MS; Pfeiffer RM; Engels EA
J Natl Cancer Inst; 2021 Feb; 113(2):199-207. PubMed ID: 32462187
[TBL] [Abstract] [Full Text] [Related]
7. Factors Associated With Receipt of Partial Nephrectomy or Minimally Invasive Surgery for Patients With Clinical T1a and T1b Renal Masses: Implications for Regionalization of Care.
Sterling J; Rivera-Núñez Z; Patel HV; Farber NJ; Kim S; Radadia KD; Modi PK; Goyal S; Parikh R; Weiss RE; Kim IY; Elsamra SE; Jang TL; Singer EA
Clin Genitourin Cancer; 2020 Dec; 18(6):e643-e650. PubMed ID: 32389458
[TBL] [Abstract] [Full Text] [Related]
8. Mucinous Tubular and Spindle-Cell Carcinoma of the kidney: Clinical Features, Genomic Profiles, and treatment Outcomes.
Ged Y; Chen YB; Knezevic A; Donoghue MTA; Carlo MI; Lee CH; Feldman DR; Patil S; Hakimi AA; Russo P; Voss MH; Motzer RJ
Clin Genitourin Cancer; 2019 Aug; 17(4):268-274.e1. PubMed ID: 31151928
[TBL] [Abstract] [Full Text] [Related]
9. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
[TBL] [Abstract] [Full Text] [Related]
10. [Segmental vena cava resection for the treatment of renal tumor with invading tumor thrombus].
Ye JF; Ma LL; Zhao L; Wang GL
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Feb; 50(1):183-187. PubMed ID: 29483744
[TBL] [Abstract] [Full Text] [Related]
11. Results of the Third AIEOP Cooperative Protocol on Wilms Tumor (TW2003) and Related Considerations.
Spreafico F; Biasoni D; Lo Vullo S; Gandola L; D'Angelo P; Terenziani M; Bianchi M; Provenzi M; Indolfi P; Pession A; Nantron M; Di Cataldo A; Morosi C; Perotti D; Catania S; Bellani FF; Collini P;
J Urol; 2017 Nov; 198(5):1138-1145. PubMed ID: 28655531
[TBL] [Abstract] [Full Text] [Related]
12. Nephron-sparing surgery for Wilms tumor: A systematic review.
Vanden Berg RN; Bierman EN; Noord MV; Rice HE; Routh JC
Urol Oncol; 2016 Jan; 34(1):24-32. PubMed ID: 26254695
[TBL] [Abstract] [Full Text] [Related]
13. Survival after relapse in children with solid tumors: a follow-up study from the Italian off-therapy registry.
Ceschel S; Casotto V; Valsecchi MG; Tamaro P; Jankovic M; Hanau G; Fossati F; Pillon M; Rondelli R; Sandri A; Silvestri D; Haupt R; Cuttini M
Pediatr Blood Cancer; 2006 Oct; 47(5):560-6. PubMed ID: 16395684
[TBL] [Abstract] [Full Text] [Related]
14. Misteltoe (Iscador) therapy in stage IV renal adenocarcinoma. A phase II study in patients with measurable lung metastases.
Kjaer M
Acta Oncol; 1989; 28(4):489-94. PubMed ID: 2477047
[TBL] [Abstract] [Full Text] [Related]
